GPE
Pleno Secures $25M Funding for Commercial Launch, Appoints New CEO from Illumina
Pleno, multiomics, funding, commercial launch, new CEO, Illumina
Negev Labs Unveils Next-Gen Psychedelic Therapies with Non-Hallucinogenic Neuroplastogens
Negev Labs, neuroplastogens, psychedelic therapies, non-hallucinogenic psychedelics, mental health treatments, biotechnology company builder
Supreme Court Declines to Review PhRMA’s Challenge to Arkansas’ 340B Contract Pharmacy Law
340B Program, Arkansas Act 1103, PhRMA, Supreme Court, Contract Pharmacies, Drug Pricing, Federal Preemption
BIOSECURE Act Excluded from US Defense Bill, Offering Reprieve to Chinese Biotechs
BIOSECURE Act, Chinese biotechs, US defense bill, biotechnology supply chains, national security concerns
GSK Extends Shingrix Collaboration with Zhifei in China, Explores RSV Vaccine Partnership
GSK, Zhifei, Shingrix, RSV vaccine, Arexvy, China, vaccine collaboration
Novartis Reveals Sustained Efficacy and Safety of Fabhalta in Patients Switching from Anti-C5 Therapies for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Fabhalta (iptacopan), Paroxysmal Nocturnal Hemoglobinuria (PNH), Anti-C5 therapies, Efficacy and safety, Switching therapies, Hemoglobin improvement, Transfusion avoidance
Agenus Announces Strategic Realignment: Focus on Core Programs, Significant Cost Reductions, and Layoffs
Agenus, strategic realignment, layoffs, cost reduction, botensilimab/balstilimab (BOT/BAL), cancer drug development
GSK Invests $546M in Rgenta’s RNA Modulation Technology for Cancer and Other Diseases
GSK, Rgenta, RNA modulation, cancer treatment, pharmaceutical investment
Ipsen and Biomunex Partner on First-in-Class MAIT Cell Engager for Solid Tumors in $610M Deal
Ipsen, Biomunex, MAIT cell engager, T cell engager, solid tumors, immuno-oncology, BMX-502, BiXAb technology, GPC3 tumor antigen.
Sanofi Invests €1 Billion in Beijing to Enhance Insulin Production Capacity
Sanofi, insulin production, Beijing, investment, pharmaceutical industry